within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XF02_Alitretinoin;

model Alitretinoin
  extends Pharmacolibrary.Drugs.ATC.L.L01XF02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01XF02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Alitretinoin (9-cis-retinoic acid) is a retinoid approved for the treatment of severe chronic hand eczema unresponsive to topical corticosteroids. It is also under investigation or historical use for AIDS-related Kaposi's sarcoma. Alitretinoin acts on both retinoid X receptors (RXRs) and retinoic acid receptors (RARs), modulating cell growth and differentiation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters are based on healthy adults from data compiled in regulatory submissions and review articles. Published PK studies are limited; below values are derived from secondary sources and drug monographs.</p><h4>References</h4><ol><li><p>Schmitt-Hoffmann, AH, et al., &amp; Kovacs, P (2012). Oral alitretinoin: a review of the clinical pharmacokinetics and pharmacodynamics. <i>Expert review of clinical pharmacology</i> 5(4) 373–388. DOI:<a href=\"https://doi.org/10.1586/ecp.12.26\">10.1586/ecp.12.26</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22943117/\">https://pubmed.ncbi.nlm.nih.gov/22943117</a></p></li><li><p>Schmitt-Hoffmann, AH, et al., &amp; Maares, J (2011). Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate. <i>Clinical and experimental dermatology</i> 36 Suppl 2 4–11. DOI:<a href=\"https://doi.org/10.1111/j.1365-2230.2011.04031.x\">10.1111/j.1365-2230.2011.04031.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21443598/\">https://pubmed.ncbi.nlm.nih.gov/21443598</a></p></li><li><p>Schmitt-Hoffmann, AH, et al., &amp; Maares, J (2011). Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). <i>Clinical and experimental dermatology</i> 36 Suppl 2 18–23. DOI:<a href=\"https://doi.org/10.1111/j.1365-2230.2011.04033.x\">10.1111/j.1365-2230.2011.04033.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21443600/\">https://pubmed.ncbi.nlm.nih.gov/21443600</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Alitretinoin;
